# a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY

> **NCT04290611** · — · COMPLETED · sponsor: **Groupe Hospitalier Pitie-Salpetriere** · enrollment: 500000 (actual)

## Conditions studied

- Prostate Cancer
- Neuropathy
- Epilepsy
- Encephalopathy

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT04290611
- **Lead sponsor:** Groupe Hospitalier Pitie-Salpetriere
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-04-08
- **Target enrollment:** 500000 (ACTUAL)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04290611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04290611, "a Vigibase Pharmacovigilance Study of ENzalutamide Drug-induced neurotoxicitY". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04290611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*